Product Name | Human PD - L1 inhibitor IV |
Size | 1 mg |
Catalog # | AS-65584 |
US$ | $196 |
Purity | Peak Area by HPLC ≥95% |
Programed cell death protein 1 (PD-1) is a cell surface receptor. PD-1 and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Several types of cancer cells overexpress PD-L1 in order to escape from the PD-1/PD-L1 immunosurveillance mechanism. Human PD-L1 inhibitor IV is a peptide-based molecule. It binds to human PD-1 and inhibits PD-1/PD-L1 binding.This peptide, hPDL-1 inhibitor IV has anchor residues (underlined), GNWDYNSQRAQLYNQ that influence binding of hPD-L1 to hPD-1. Developing inhibitors specifically blocking the PD-1/PD-L1 pathway has become a popular approach toward cancer treatment.PD-L1 Related Peptides:Human PD-L1 inhibitor I, Cat# AS-65581Human PD-L1 inhibitor II, Cat# AS-65582Human PD-L1 inhibitor III, Cat# AS-65583Human PD-L1 inhibitor V, Cat# AS-65585 | |
Detailed Information | DatasheetMaterial Safety Data Sheets (MSDS) |
References | Bardhan K., et.al, Front Immunol 7(550), (2016); Li Q., et.al, Oncotarget 7(40), 64967-64976 (2016); D"Errico G., et.al, Clin Transl Med 6(1), 3-12 (2017) |
Molecular Weight | 1857.0 |
GNWDYNSQRAQLYNQ | |
Sequence(Three-Letter Code) | H - Gly - Asn - Trp - Asp - Tyr - Asn - Ser - Gln - Arg - Ala - Gln - Leu - Tyr - Asn - Gln - OH |